COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
Anne M. Hause, Paige Marquez, Bicheng Zhang, Tanya R. Myers, Julianne Gee, John R. Su, Casey Parker, Deborah Thompson, S. Panchanathan, Tom T. Shimabukuro, David K. Shay
Abstract
The Pfizer-BioNTech COVID-19 vaccine for use in children aged 6 months-4 years was administered as 3 doses (3 g [0.2 mL] each), at intervals of 3 weeks between doses 1 and 2 and 8 weeks between doses 2 and 3; the Moderna COVID-19 vaccine for use in children aged 6 months-5 years was administered as 2 doses (25 g [0.25 mL] each), 4 weeks apart. Data for Moderna COVID-19 doses administered to children aged 5 years were unavailable.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyPediatricsInternal medicineOutbreakInfectious disease (medical specialty)DiseaseViral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiology